GLP-1 Drug Dulaglutide Triggered Severe Diabetic Ketoacidosis in Patient With Undiagnosed LADA
A 50-year-old woman diagnosed with type 2 diabetes developed severe diabetic ketoacidosis within a day of starting dulaglutide — revealing she actually had latent autoimmune diabetes in adults (LADA).
Quick Facts
What This Study Found
A patient misdiagnosed as type 2 diabetes developed severe DKA within 24 hours of starting dulaglutide and discontinuing insulin, leading to her correct diagnosis of LADA.
Key Numbers
One documented case of DKA in a T2D patient on dulaglutide — rare but clinically significant.
How They Did This
Single case report documenting clinical presentation, diagnostic workup, emergency treatment, and outcome of GLP-1 agonist-induced DKA in a patient subsequently diagnosed with LADA.
Why This Research Matters
As GLP-1 drugs are prescribed to millions for diabetes and weight loss, cases like this highlight the importance of correctly identifying diabetes type before prescribing. LADA is frequently misdiagnosed as type 2 diabetes, and GLP-1 drugs cannot replace insulin in autoimmune diabetes.
The Bigger Picture
Up to 10% of people diagnosed with type 2 diabetes may actually have LADA. As GLP-1 prescriptions surge for both diabetes and obesity, correctly identifying which patients have autoimmune beta-cell destruction becomes critical for safety. This case serves as a warning that GLP-1 drugs are not suitable replacements for insulin in LADA or type 1 diabetes.
What This Study Doesn't Tell Us
Single case report — the weakest form of clinical evidence. The patient had multiple risk factors (12-year disease duration, insulin discontinuation, potential LADA). DKA could have been triggered primarily by stopping insulin rather than by dulaglutide itself. Cannot generalize to all GLP-1 drug users.
Questions This Raises
- ?Should LADA screening (anti-GAD antibodies, C-peptide) be routine before starting GLP-1 drugs in diabetes patients?
- ?How many cases of GLP-1-associated DKA involve undiagnosed LADA or late-onset type 1 diabetes?
- ?Are there warning signs that could help clinicians identify LADA patients before prescribing GLP-1 drugs?
Trust & Context
- Key Stat:
- DKA in 24 hours after first dulaglutide injection and insulin discontinuation in a patient with undiagnosed LADA
- Evidence Grade:
- Preliminary evidence: single case report. While clinically instructive, one case cannot establish causation or risk frequency.
- Study Age:
- Published in 2024. Relevant to current GLP-1 prescribing practices.
- Original Title:
- GLP-1 receptor agonist-induced diabetic ketoacidosis: A case report.
- Published In:
- Medicine, 103(39), e39799 (2024)
- Authors:
- Zhang, Jiaming, Ma, Ying(2), Zu, Qianhe, Wang, Xiaohui, Zhang, Yao
- Database ID:
- RPEP-09638
Evidence Hierarchy
Frequently Asked Questions
Can GLP-1 drugs cause diabetic ketoacidosis?
DKA with GLP-1 drugs is extremely rare but has been reported, particularly in patients who actually have LADA or type 1 diabetes rather than true type 2 diabetes. GLP-1 drugs do not produce insulin and cannot replace it in patients whose insulin-producing cells are destroyed.
What is LADA and why does it matter for GLP-1 drugs?
LADA (Latent Autoimmune Diabetes in Adults) is a slow-onset autoimmune diabetes often misdiagnosed as type 2. Unlike T2D, LADA patients eventually lose all insulin production. GLP-1 drugs work by boosting existing insulin release — if there are no functioning beta cells, the drugs cannot work and stopping insulin can be dangerous.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09638APA
Zhang, Jiaming; Ma, Ying; Zu, Qianhe; Wang, Xiaohui; Zhang, Yao. (2024). GLP-1 receptor agonist-induced diabetic ketoacidosis: A case report.. Medicine, 103(39), e39799. https://doi.org/10.1097/MD.0000000000039799
MLA
Zhang, Jiaming, et al. "GLP-1 receptor agonist-induced diabetic ketoacidosis: A case report.." Medicine, 2024. https://doi.org/10.1097/MD.0000000000039799
RethinkPeptides
RethinkPeptides Research Database. "GLP-1 receptor agonist-induced diabetic ketoacidosis: A case..." RPEP-09638. Retrieved from https://rethinkpeptides.com/research/zhang-2024-glp1-receptor-agonistinduced-diabetic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.